Clinical Trials Logo

Clinical Trial Summary

Incidence of digestive neuroendocrine tumors are increasing. Analysis of individual microbiota is a way to explore new neoplastic mechanisms, tumor identification and therapeutic orientations. This prospective pilot study aims to describe fecal bacterial phylogeny of patients with digestive neuroendocrine tumor.

Bacterial genomic signature will be recorded at initiation of Lanreotide treatment in naive patient with digestive neuroendocrine tumor (pancreas or small intestine), metastatic or locally advanced, as well as after one year follow up.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04198402
Study type Observational
Source Assistance Publique - Hôpitaux de Paris
Contact IRADJ SOBHANI, MD-PHD
Phone 01 49 81 23 62
Email iradj.sobhani@aphp.fr
Status Not yet recruiting
Phase
Start date January 2020
Completion date January 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05607745 - Dietary Counseling Coupled With FMT in the Treatment of Obesity and NAFLD - the DIFTOB Study N/A
Completed NCT03497806 - Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiotaâ„¢ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection Phase 2
Not yet recruiting NCT06423508 - PRObing The Efficacy of Commercial Stage Storage Buffers and Evaluating Gut Metaproteome Variability Between Individuals
Completed NCT02500563 - Exploratory/Proof of Principle Microbiota Study N/A
Completed NCT04835727 - Effect of Semi-vegetarian Diet in Inflammatory Bowel Disease Patients With Clinical Remission N/A
Completed NCT02677649 - Microbiota Diversity and Composition and Polyphenol Bioavailability N/A